Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.

What Was Tested

This randomized controlled trial looks at Glutathione.

To assess the relationship between serum free mGSTP1 and treatment outcomes in SYNERGY, a phase 3 multicentre randomised trial testing the addition of custirsen to first-line chemotherapy with docetaxel in mCRPC.

Who Took Part

The abstract describes 600 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.

Serum free mGSTP1 DNA was measured by a sensitive methylation-specific polymerase chain reaction assay in paired samples (baseline and after two cycles of docetaxel) from 600 patients.

This marker may accelerate future clinical trials of new therapies and be useful in the clinic to guide treatment decisions.

How the Study Was Run

The design is described as randomized and multicenter.

Because people in this Glutathione study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Running at several centres spread the Glutathione study over different clinics and patient groups.

In this study, the researchers confirmed that a blood marker predicted outcomes after chemotherapy for metastatic prostate cancer.

What Was Measured

Topics PubMed links to this paper include Antineoplastic Agents, DNA, DNA Methylation, Disease-Free Survival, Docetaxel, Glutathione Transferase and Neoplasm Metastasis.

Author keywords: Biomarker, Chemotherapy, Glutathione S transferase 1, Metastatic castration-resistant prostate cancer, Prognosis and Therapeutic response.

What This Means in Plain Language

The paper is a randomized and multicenter study of Glutathione in 600 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (European urology), a journal based in Switzerland.

More context: the Glutathione compound page, all human trials.